Welcome to
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
I am a healthcare professional in the US
I am a healthcare professional outside the US

Now included 4 Clinical Practice Guidelines

This site is intended for US residents only.

Prognostic significance: proven in the ABCSG-8 study

Study consisted of more than 1400 patient samples1

  • Study cohort consists of formalin-fixed paraffin-embedded (FFPE) breast tumor tissue samples retrospectively collected and archived in the Austrian Breast & Colorectal Cancer Study Group (ABCSG) tumor bank from patients enrolled in the ABCSG-8 trial1
  • Postmenopausal women with hormone receptor–positive breast cancer were randomized prior to treatment to 2 years of adjuvant tamoxifen followed by either 3 years of anastrozole or 3 years of adjuvant tamoxifen1,2
  • Reconsented >1200 patients2
  • Clinical treatment score (CTS) was derived from standard clinical covariates, including age, grade, tumor size, nodal status, and adjuvant therapy1
Treatment structure of ABCSG-8 trial

ABCSG-8 objectives1

  • Determine whether the Prosigna Score adds prognostic information beyond the CTS
  • Determine whether the Prosigna Score–based risk groups of low, intermediate, and high add prognostic information beyond the CTS

Get more prognostic information beyond standard clinical variables

  • Both the Prosigna Score and risk group add statistically significant prognostic information beyond the CTS (P<0.0001)1,2
  • In node-negative patients, the 10-year distant recurrence-free survival (DRFS) rates were >95% for the low-risk group, 90.4% for the intermediate-risk group, and <85% for the high-risk group1
  • In node-positive patients, the 10-year DRFS rates were 94.2% for the low-risk group and 75.8% for the high-risk group1
DRFS by Prosigna Score-based risk subgroup
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Gnant M, Filipits M, Greil R, et al; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25(2):339-345.